News Glialogix Drug for Progressive MS Funded by National Multiple Sclerosis Society Glialogix Drug for Progressive MS Funded by National Multiple Sclerosis Society by Patricia Silva, PhD | October 1, 2014 Share this article: Share article via email Copy article link San Francisco Bay Area-based Glialogix, Inc., a biopharmaceutical company that specializes in developing novel treatments for multiple sclerosis (MS), announced yesterday that they have closed aĀ Sponsored Research Agreement with Fast Forward, a non-profit organizationĀ that aims to accelerate MS treatment development.Ā Glialogix will receive funding for one of their pipeline products for neuroprotection, GLX1112, which has shown efficacy in slowing disability progression and potentially repairing neuronal damage — one of the main priorities of the National Multiple Sclerosis Society (NMSS). Fast Forward, founded by the NMSS, will be supporting Glialogix through cutting-edge pharmacokinetic testing, preclinical models and mechanistic research on GLX1112. According to Thad Reeder, Ph.D., the company’s CSO and lead researcher for the drug, it has already shown promising results in progressive forms of MS. [adrotate group=”4″] Glialogix CEO,Ā Mark Moore, Ph.D., explained that there is a great need for effective treatments for progressive MS, as this type tends to cause the most disability and does not respond to treatments indicated for relapsing MS. At present, while there are several drugs being tested for treating progressive forms of MS, most patients are treated with RRMS therapies, as these are the only drugs approved by the FDA for treating progressive MS in the United States. In other countries, progressive MS patients often have no access to therapies, and are forced to cope with symptoms and disabilities on their own. Dr. Moore concluded by stating that he looks forward to collaborating with Fast Forward on the development of a viable progressive MS therapy, and is confident this new agreement is the boostĀ GLX1112 is waiting for. Multiple sclerosis can be a frustrating condition to live with. Researchers from the Kessler Foundation suggest that MS patients can benefit greatly from regular participation in a wellness program. Their study reports improvements in patients’Ā mood,Ā mental health, perceived stress, and pain. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Fast Forward, National Multiple Sclerosis Society, progressive multiple sclerosis
April 17, 2024 News by Steve Bryson, PhD NfL blood levels predict CIS to MS conversion: Clinical trial data
April 16, 2024 News by Marisa Wexler, MS Patients deem AI-based ChatGPT more empathetic than neurologists